Serum-based immunoassays have been used to detect oxidative injury pertinent to AβPP-Aβ and phospho-tau accumulations [198] or insulin/IGF-related metabolic impairments [210, 211] in AD brains. This evidence concerns the gene MAPT and Alzheimer disease.